---

---

published : This month    tags : Clinical-trials-phase-ii   

save search

---

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $5.595 16.56% 2.4M |

Health Technology

| -4.21% | O: 10.02% H: 0.0% C: 0.0%
bb-301 first positive biopharma for trial opmd study

---

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | News | $11.515 -1.07% 33K |

Health Technology

| -1.49% | O: -1.49% H: 0.0% C: 0.0%
jeuveau publication for study

---

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | News | $2.6 4.6K |

Health Technology

| 4.43% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

---

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $12.94 2.94% 330K |

Health Technology

| -17.57% | O: -15.02% H: 3.55% C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study

---

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $265.48 0.53% 360K |

Health Technology

| 0.54% | O: 0.41% H: 0.0% C: 0.0%
tezspire copd

---

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
PTCHF | $2.78 19.97% 560 |

n/a

| Email alert Add to watchlist
lyt-100 fibrosis trial

---

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $144.86 0.06% 2.8M |

Health Technology

| -2.32% | O: -0.04% H: 0.0% C: 0.0%
avb-101 first dementia for trial

---

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Published: 2024-04-10 (Crawled : 14:00) - biospace.com/
AMLX | $2.03 1.5% 250K |

| -24.72% | O: -2.62% H: 1.54% C: -5.38%
amx0035 control pancreatic ongoing pharmaceuticals trial

---

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.82 0.68% 62K |

Manufacturing

| -31.44% | O: -16.22% H: 0.99% C: -7.89%
first melanoma update therapeutics advanced

---

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
MRNA | News S | $101.87 -1.52% 710K |

Health Technology

| -0.16% | O: -0.59% H: 2.09% C: -1.74%
rna-3927 mrna therapy

---

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
MRK | $124.9 -0.38% 1.4M |

Health Technology

| -3.82% | O: 0.13% H: 0.0% C: 0.0%
cancer trial initiated

---

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.785 -0.25% 150K |

Health Technology

| -14.62% | O: 2.25% H: 4.0% C: 1.0%
alg-0550 first therapeutics study

---

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $393.86 0.19% 160K |

Health Technology

| -5.96% | O: 0.56% H: 0.0% C: 0.0%
vx-147 disease kidney treatment trial

---

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA | $89.77 -0.62% 170K |

Health Services

| -1.24% | O: -0.6% H: 2.8% C: 2.25%
cancer trials trial

---

Gainers vs Losers

83%

17%

Top 10 Gainers

AGBA | $0.7995 99.88% 73M |

Finance

BPTH | $6.21 91.67% 58M |

Health Technology

INVO | $1.36 78.95% 3.6M |

Health Technology

TIRX | $0.8258 70.34% 50M |

ISPC | $0.307 44.13% 3.6M |

Professional, Scientific, and T...

SINT | $0.0504 35.12% 300M |

Health Technology

VTNR S | $1.295 32.25% 5.5M |

Industrial Services

ALRN | $5.53 30.12% 250K |

Health Technology

SMSI 4 | $2.53 29.74% 510K |

Technology Services

HOLO | $2.86 27.68% 28M |

---

Your saved searches

---